Filing Details
- Accession Number:
- 0001209191-16-111282
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2016-03-31 18:42:55
- Reporting Period:
- 2016-03-29
- Filing Date:
- 2016-03-31
- Accepted Time:
- 2016-03-31 18:42:55
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1175505 | Five Prime Therapeutics Inc | FPRX | Pharmaceutical Preparations (2834) | 260038620 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1475714 | T Lewis Williams | Two Corporate Drive South San Francisco CA 94080 | President, Ceo And Chairman | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2016-03-29 | 9,215 | $6.89 | 349,743 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2016-03-29 | 9,215 | $40.01 | 340,528 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2016-03-30 | 14,044 | $6.89 | 354,572 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2016-03-30 | 14,044 | $40.02 | 340,528 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Employee Stock Option (right to buy) | Disposition | 2016-03-29 | 9,215 | $0.00 | 9,215 | $6.89 |
| Common Stock | Employee Stock Option (right to buy) | Disposition | 2016-03-30 | 14,044 | $0.00 | 14,044 | $6.89 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 28,501 | 2020-07-28 | No | 4 | M | Direct | |
| 14,457 | 2020-07-28 | No | 4 | M | Direct |
Footnotes
- Includes 176 shares granted to the reporting person by Five Prime Therapeutics, Inc. (the "Company") pursuant to a company match under the Company's 401(k) plan.
- The sales reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on November 4, 2015.
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $40.00 to $40.075, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 3 and 4 to this Form 4.
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $40.00 to $40.05, inclusive.
- This option is fully vested and immediately exercisable.
Billionaire Hedge Funds
